Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 9/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL195619 | 0.98 | CHRNA7 (0.47) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| Bromide SCHEMBL1140066 | 0.98 | CHRNA7 (0.50) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL8346963 | 0.92 | CHRNA7 (0.43) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL4258543 | 0.90 | CHRNA7 (0.42) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| SCHEMBL10256548 | 0.89 | CHRNA7 (0.52) | CHRNA7CHRM3ACHECHRM2CHRNB2 | |
| Hydrochloric Acid SCHEMBL11194479 | 0.88 | CHRNA7 (0.47) | CHRNA7CHRM3ACHECHRNB2CHRNA4 | |
| SCHEMBL4256635 | 0.86 | CHRNA7 (0.45) | CHRNA7CHRM3ACHECHRM2 | |
| Trifluoromethanesulfonic Acid SCHEMBL8349313 | 0.85 | CHRNA7 (0.39) | CHRNA7CHRM3ACHECHRM2 | |
| SCHEMBL10257199 | 0.81 | KCNH2 (0.48) | CHRNA7CHRM3CHRM2 | |
| SCHEMBL3681307 | 0.79 | CHRNA7 (0.60) | CHRNA7CHRM3ACHECHRM2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| EP-3924054-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| CN-113490528-A | 3- (1-oxo-5- (piperidine-4-yl) isoindoline-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| WO-2020165833-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2020-08-20 | — | — | WO | disclosed |
| EP-3397616-B1 | LSD1 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2020108579-A1 | AMINO-SUBSTITUTED PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | EURO-CELTIQUE S.A. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | EURO-CELTIQUE S.A. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008095558-A2 | BLEACHING AGENT COMPRISING PIPERIDONE/S AND IMIDAZOLE/S | HENKEL AG & CO. KGAA (DE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-7192964-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRNA7 3220/4885CHRM3 4035/4885ACHE 2753/4885 |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRK1, OPRD1 | CHRNA7 298/4885CHRM3 385/4885ACHE 823/4885 |
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | CHRNA7 3399/4885CHRM3 3428/4885ACHE 3147/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | CHRNA7 1022/4885CHRM3 540/4885ACHE 1899/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | CHRNA7 1144/4885CHRM3 719/4885ACHE 2047/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRNA7 3220/4885CHRM3 4035/4885ACHE 2753/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRNA7 3220/4885CHRM3 4035/4885ACHE 2753/4885 |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | CNR2, CNR1, TRPV1 | CHRNA7 328/4885CHRM3 706/4885ACHE 265/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | CHRNA7 3152/4885CHRM3 2800/4885ACHE 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.